Warburg Pincus trims stake in China Biologic

The US private equity firm raises $241.5 million after paring stake in the Nasdaq-listed biopharmaceutical firm.

Warburg Pincus trims stake in China Biologic

Warburg Pincus has raised $241.5 million following a share sale in China Biologic Products.

The US private equity firm saw its stake decrease from 44.2% to 34% after the sale, according to a source close to the deal.

The sale in the Nasdaq-listed biopharmaceutical company has been marketed for the past few days in the US, which contributed to a decline in share price performance. After hitting $120.85 per unit on...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES